Biodesix Announces Data To Be Presented at AACR Annual Meeting 2018
April 05, 2018 10:00 ET
|
Biodesix, Inc.
BOULDER, Colo., April 05, 2018 (GLOBE NEWSWIRE) -- Biodesix®, Inc. will present new data confirming the ability of the company’s droplet digital PCR (ddPCR™)-based platform to reliably detect key...
Biodesix Announces Biomarker Research Collaboration with Checkmate Pharmaceuticals
March 20, 2018 09:00 ET
|
Biodesix, Inc.
BOULDER, Colo., March 20, 2018 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Boulder, CO, USA), a molecular diagnostics company has entered into a biomarker research collaboration with Checkmate...
Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners
March 05, 2018 13:26 ET
|
Biodesix, Inc.
BOULDER, Colo., March 05, 2018 (GLOBE NEWSWIRE) -- Biodesix, Inc., a molecular diagnostics company that develops and commercializes non-invasive, blood-based diagnostic tests for oncology, today...
Biodesix Announces PD-L1 Collaboration with Professor Fred R. Hirsch
January 31, 2018 09:00 ET
|
Biodesix, Inc.
BOULDER, Colo., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Biodesix® announced a new collaboration agreement with PD-L1 expert Professor Fred R. Hirsch, MD, PhD, laboratory director at the Hirsch Biomarker...
MEDIA ADVISORY -- Dr. Heinrich Roder, Biodesix CTO, To Speak At Precision Medicine World Conference
January 19, 2018 16:56 ET
|
Biodesix, Inc.
ADVISORY, Jan. 19, 2018 (GLOBE NEWSWIRE) -- WHAT: Dr. Heinrich Roder, Biodesix’ CTO, will speak on “Applied Machine Learning for Immuno-Oncology Diagnostics” in the “AI and Data Science Showcase”...
Data Published In AACR Journal Suggest Biodesix® Test in Development May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors
December 20, 2017 10:00 ET
|
Biodesix, Inc.
BOULDER, Colo., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Findings published in the American Association for Cancer Research (AACR) peer-reviewed journal Cancer Immunology Research demonstrate that a test...
Biodesix Leaders Share Commercial and Pipeline Updates at Annual qPCR and dPCR Congress
December 05, 2017 06:00 ET
|
Biodesix, Inc.
BOULDER, Colo., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Biodesix provided updates and data related to the company’s on-market and in-development liquid biopsy tests at the 2017 qPCR & Digital PCR...
Biodesix Announces New Data Demonstrating Analytic Validity of Automated RNA Extraction from Plasma with the GeneStrat® Test
November 16, 2017 15:40 ET
|
Biodesix, Inc.
BOULDER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Biodesix® announced data demonstrating that a novel, automated method for extracting circulating RNA from plasma performed equivalently or better...
Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients
November 07, 2017 12:22 ET
|
Biodesix, Inc.
BOULDER, Colo., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Biodesix® chief technology officer, Dr. Heinrich Roder, will give an oral presentation discussing a proprietary test development methodology that...
Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry
November 01, 2017 12:12 ET
|
Biodesix, Inc.
BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Biodesix® presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data...